29.69

4.80% 1.36

Rapport Therapeutics Inc (RAPP)

Overview News Price History Option Chain Financials Discussions Forecast

Rapport Therapeutics Inc stock is traded at $29.69, with a volume of 137.12K. It is up +4.80% in the last 24 hours and down -30.44% over the past month. Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Previous Close:

$28.33

Open:

$29.12

24h Volume:

137.12K

Relative Volume:

0.53

Market Cap:

$1.42B

Revenue:

$20.00M

Net Income/Loss:

$-107.28M

P/E Ratio:

-11.41

EPS:

-2.6031

Net Cash Flow:

$-80.71M

1W Performance:

-0.54%

1M Performance:

-30.44%

6M Performance:

-19.12%

1Y Performance:

+15.17%

1-Day Range:

$28.68

$30.48

1-Week Range:

$28.10

$31.20

52-Week Range:

$23.75

$52.93

Rapport Therapeutics Inc Stock (RAPP) Company Profile

Name

Rapport Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

857-321-8020

Address

99 HIGH STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

RAPP's Discussions on Twitter

Compare RAPP vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPP Rapport Therapeutics Inc	29.69	1.42B	20.00M	-107.28M	-80.71M	-2.6031
VRTX Vertex Pharmaceuticals Inc	510.13	129.30B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.70	94.90B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.21	82.49B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.03	53.33B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	370.95	41.96B	5.76B	514.49M	1.10B	4.4813

Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-26	Initiated	Guggenheim	Buy
Jul-28-26	Initiated	William Blair	Outperform
Jun-24-26	Initiated	Leerink Partners	Outperform
May-19-26	Resumed	Truist	Buy
Apr-10-26	Initiated	Raymond James	Strong Buy
Feb-02-26	Initiated	Wells Fargo	Overweight
Nov-19-25	Initiated	BTIG Research	Buy
Sep-16-25	Initiated	Truist	Buy
Aug-06-25	Initiated	H.C. Wainwright	Buy
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	Jefferies	Buy
Jul-02-24	Initiated	Stifel	Buy
Jul-02-24	Initiated	TD Cowen	Buy

View All

Rapport Therapeutics Inc Stock (RAPP) Latest News

Oct 11, 2026

Which Brain Pathways Is Rapport Therapeutics Trying to Tune? - Kalkine Media

Oct 11, 2026

Oct 10, 2026

Form 4 Rapport Therapeutics Inc For: 10 October By Investing.com - Investing.com South Africa

Oct 10, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock - Investing.com

Oct 10, 2026

Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock By Investing.com - Investing.com South Africa

Oct 10, 2026

Form 4 Rapport Therapeutics Inc For: 10 October By Investing.com - Investing.com Canada

Oct 10, 2026

Oct 06, 2026

Form 144 RAPPORT THERAPEUTICS For: 6 October By Investing.com - Investing.com Canada

Oct 06, 2026

Guggenheim Initiates Rapport Therapeutics at Buy With $65 Price Target - marketscreener.com

Oct 06, 2026

Oct 01, 2026

Form 144 Rapport Therapeutics For: 1 October By Investing.com - Investing.com Nigeria

Oct 01, 2026

Sep 28, 2026

RAPP 10-Q FilingsRapport Therapeutics, Inc. SEC 10-Q - Stock Titan

Sep 28, 2026

Spyre Therapeutics (SYRE) Stock Price, News & Analysis - Stock Titan

Sep 28, 2026

Sep 25, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com India

Sep 25, 2026

Sep 24, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com Nigeria

Sep 24, 2026

Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com India

Sep 24, 2026

Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com Canada

Sep 24, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com

Sep 24, 2026

Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com UK

Sep 24, 2026

Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com UK

Sep 24, 2026

RAPP Form 4 FilingsRapport Therapeutics, Inc. SEC Form 4 - Stock Titan

Sep 24, 2026

Sep 23, 2026